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Abstract To study the regulation of the human xanthine
oxidoreductase (XOR) gene, we cloned 1.9 kb of the promoter
region. In reporter gene assays, a construct encompassing
nucleotides between 3142 to +42 conferred maximal basal
activity of the XOR promoter in 293T cells, in comparison with
shorter (392 to +42) or longer (up to 31937 to +42) constructs.
The promoter activity was low in NIH-3T3 cells. The most active
construct contained a putative CCAAT motif at 3119 to 3123.
Electrophoretic mobility shift assays showed that this sequence
binds the ubiquitous nuclear factor Y (NF-Y). Mutation of the
CCAAT motif (CTGAT) abolished the NF-Y binding and
considerably reduced the promoter activity. Our data suggest
an important functional role for NF-Y in the transcriptional
activation of the human XOR gene. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Xanthine oxidoreductase (XOR) oxidizes hypoxanthine to
xanthine and further to urate. In this process electrons are
passed to either NAD (xanthine dehydrogenase form, EC
1.1.1.204) or molecular oxygen (xanthine oxidase form, EC
1.1.3.22), leading to the formation of NADH or superoxide
anion (O32 ) and hydrogen peroxide (H2O2), respectively [1].
The enzyme in vivo is predominantly in the dehydrogenase
form, but can be converted into the oxidase form reversibly
by sulfhydryl oxidation or irreversibly by proteolysis [2].
Based on its ability to produce reactive oxygen species,
XOR has been ascribed a role in ischemia-reperfusion injury
[3].
Because of its proposed pathogenic role, the regulation of
XOR by a number of e¡ectors has been studied. Hypoxia
elevates XOR activity in animal cells, by a mechanism that
is controversial, since both transcriptional and posttransla-
tional regulation have been implicated [4^6]. Cytokines
(IFN-Q, IL-1, IL-6, TNF-K) and dexamethasone induce both
XOR enzyme activity and mRNA expression in cultured cells
[7^9], which is in line with the proposed role of XOR in
in£ammatory conditions. During lactation there is a clear in-
crease of XOR protein levels in the mammary gland [10] and
the enzyme is present in human milk [11]. In a cell line derived
from mouse mammary gland, prolactin with dexamethasone
or cortisol increases both XOR protein and mRNA levels
[12,13].
Most of the data supporting the pathophysiological role of
XOR come from studies using experimental animals or non-
human cell lines. However, in order to assess the role of XOR
in human pathophysiology it is mandatory to study the hu-
man enzyme for two main reasons. Firstly, since urate is the
end product of purine catabolism only in man and other pri-
mates, the regulation of its production may di¡er from other
species. Secondly, the expression of the human XOR gene, at
the level of enzymatic activity, immunoreactive protein, and
mRNA is con¢ned to relatively few organs, with the highest
levels in the liver, intestine, and mammary gland [10,14],
whereas in rodents the enzyme is strongly expressed in several
organs [15,16].
The cDNA of the human XOR gene has been cloned
[17,18], and its structure as well as the sequence of 2 kb of
its 5P-untranslated region have been published [19]. The gene
has been localized to chromosome 2p22 [20,21]. In the only
reported functional study of the human XOR promoter, re-
pressing elements, speci¢cally an E-box and a TATA-like el-
ement, were identi¢ed and a considerably lower level of tran-
scription of the human gene compared to the mouse XOR
gene was shown [22]. Activating transcription factors of the
human XOR promoter have not been described.
The aim of this study was to identify promoter regions with
potential regulatory importance, and to analyze, which pro-
tein(s) may play a role in transcriptional regulation of the
human XOR gene.
2. Materials and methods
2.1. Plasmids
Five human XOR gene promoter fragments were isolated by PCR
either from human genomic DNA (XOR1 and XOR2) or by using
XOR2 as the template (XOR4, XOR5, and XOR6). The primers were
designed on the basis of the sequence of the human XOR gene pro-
moter [19] and included restriction enzyme sites for BglII or MluI in
their 5P-ends and for HindIII in 3P-ends. The 5P-primer sequences were
5P-GGGAAGATCTTGTGGTTTGTAGGATGTTTAGT-3P (com-
plementary to nucleotides 31937 to 31913 in the human sequence,
underlined), 5P-GGGGACGCGTCTTACTTAAGGAAGGCTGGC-
3P (31174 to 31153), 5P-GTGGAGATCTTAATTTGCTGTGTGT-
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GATTGTT-3P (3224 to 3203), 5P-CTGAAGATCTGAGCTGG-
TTCCCTCCCATTG-3P (3142 to 3120), and 5P-TGGGACGCG-
TAACTTTCAGGTCACAGAGCA-3P (392 to 369) corresponding
to promoter fragments in XOR1, XOR2, XOR4, XOR5 and XOR6,
respectively (Fig. 1A). The 3P-primer sequence for all PCR reactions
was 5P-CTACTAAGCTTTCTGCCATTCACAAAGAAAAC-3P (+42
to +19). XOR3 was obtained by shortening XOR1 by exonuclease III
digestion (Erase-a-Base System, Promega) and its sequence corre-
sponds to nucleotides 3547 to +42. All promoter constructs were
sequenced and the sequence of XOR1 was submitted to GenBank
(GenBank AF203979). XOR5mut [23] was created by PCR using
XOR2 as the template. The mutagenic primer was 5P-CTGAA-
GATCTGAGCTGGTTCCCTCCCATCAGTGGACCT-3P (mutated
base pairs underlined), the 5P-end of the primer including a BglII
site. The 3P-primer was as above. The PCR products and XOR3
were cloned into pGL3-basic (Promega) bearing a luciferase gene.
2.2. Cell culture and transfection
Human embryonic kidney 293T cells (from Dr. Kalle Saksela, Uni-
versity of Tampere, Finland) were maintained in Dulbecco’s modi¢ed
Eagle’s medium (DMEM) containing 10% fetal bovine serum, 100
U/ml penicillin and 100 Wg/ml streptomycin. NIH-3T3 mouse ¢bro-
blasts (from ATCC) were cultured in DMEM supplied with 10% calf
serum and antibiotics as above. 24 h before transfection the 293T cells
were seeded on 12-well plates (2U105 cells per well), NIH-3T3 cells on
6-well plates (3U105 per well), and transfected with 0.5 Wg or 1 Wg of
XOR promoter constructs, respectively, using FuGene6 (Roche Mo-
lecular Biochemicals) transfection reagent. In all experiments, 10 ng
(293T cells) or 0.5 Wg (NIH-3T3 cells) of pCMVL (Clontech), a L-
galactosidase expression vector, were cotransfected to monitor trans-
fection e⁄ciency, and empty pGL3-basic vector was used as a control.
Medium was changed 16 h after transfection and the cells were further
incubated for 24 h. Luciferase activity was determined with reagents
from Promega using a Luminoskan RT reader (Labsystems). L-Ga-
lactosidase activity was determined according to Rosenthal [24].
2.3. Nuclear protein extracts
Cells were harvested in ice-cold PBS and nuclear protein extracts
were prepared as described [25]. Brie£y, after lysis in a bu¡er contain-
ing 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM
Fig. 1. Activity of the human XOR promoter luciferase constructs. A: Relative reporter activity in transiently transfected 293T cells. The cells
were transfected with 0.5 Wg of XOR constructs of indicated lengths or with pGL3-basic (pGL3) alone. B: Relative reporter activity in transi-
ently transfected NIH-3T3 cells. The cells were transfected with 1 Wg of XOR constructs or pGL3-basic alone. The bars show luciferase activity
relative to L-galactosidase activity. The relative values for the empty pGL3-basic were set as 1. The data are the means þ S.D. of at least three
independent experiments, each performed in triplicate. C: Human XOR promoter sequence from 3224 to +42 aligned with the sequence of the
rat XOR promoter. The 5P-ends of XOR4, XOR5, and XOR6 are indicated. The mutated nucleotides in XOR5mut are shown on top of the
human sequence in boldface type. The human sequence corresponding to oligo1 is underlined. The inverted CCAAT motifs are indicated with
boxes, and the C/EBP binding sites of the rat promoter sequence are underlined. The potential transcriptional initiation sites at 359 and 381
are indicated with arrows. The translational initiation codon is double underlined.
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dithiothreitol, 0.5 mM PMSF, 3 Wg/ml leupeptin and 5 Wg/ml pepsta-
tin, the cells were left on ice for 15 min and then vortexed for 10 s.
After centrifugation for 5 s at 14 000 rpm in an Eppendorf centrifuge,
proteins from the nuclear pellet were extracted for 20 min on ice in a
bu¡er (20 Wl/nuclei from 107 cells) containing 20 mM HEPES, pH 7.9,
25% (vol./vol.) glycerol, 1.5 mM MgCl2, 0.2 mM EDTA, 420 mM
NaCl, 1 mM dithiothreitol, 0.5 mM PMSF, 3 Wg/ml leupeptin and
5 Wg/ml pepstatin. Nuclear debris was removed by centrifugation for
5 min at 4‡C at 14 000 rpm in an Eppendorf centrifuge. Protein con-
centrations were measured using Bio-Rad DC protein assay (Bio-Rad
Laboratories) and the extracts were stored in aliquots at 380‡C.
2.4. Electrophoretic mobility shift assay (EMSA)
EMSA probes XOR5E and XOR5Emut were created by digesting
the plasmids XOR5 and XOR5mut with BglII and HindIII. The re-
striction fragments were puri¢ed on 8% polyacrylamide gel. Oligo1
(Fig. 1C) was prepared by annealing the oligonucleotides 5P-
GAGCTGGTTCCCTCCCATTGGTGGACCTTATTT-3P and 5P-
AATGAAATAAGGTCCACCAATGGGAGGGAACCA-3P and pu-
rifying the annealed oligonucleotide on polyacrylamide gel. NF-Y/
CBF (CCAAT binding factor) and C/EBP (CCAAT/enhancer binding
protein) consensus double-stranded oligomers and the mutated C/EBP
oligomer used in competition assays were purchased from Santa Cruz.
The antibodies for supershift assays were from Santa Cruz (C/EBP-L,
sc-150X; CBF-A/NF-Y-B, sc-7711X, and GATA-6, sc-7244X, used
as an unrelated antibody). The probes were 5P-end-labelled with
[Q-32P]ATP using T4 polynucleotide kinase (Promega). Nuclear proteins
(10 Wg) were incubated on ice for 10 min with 2 Wg poly(dI-dC)(dI-dC)
(Amersham Pharmacia Biotech) in 20 mM HEPES (pH 7.9), 10%
glycerol (vol./vol.), 50 mM KCl, 0.5 mM EDTA, 1 mM DDT,
1 mM MgCl2, 0.5 mM PMSF and 1 WM leupeptin. A 5P-end-labelled
probe (5000^10000 cpm) was then added and the incubation was
continued at 22‡C for 30 min. In the competition experiments, 10^
100-fold molar excess of the unlabelled probe was added before the
labelled probe as described in the ¢gure legends. Reaction products
were separated on 4% polyacrylamide gels run in 22.5 mM Tris-bo-
rate, 0.5 mM EDTA for 2^3 h at 200 V at 22‡C. After electrophoresis,
the gels were dried and visualized by autoradiography. In the super-
shift assays, the antibodies (2 Wg/20 Wl incubation vol.) were added
after binding reactions and incubation was further continued for 50
min at 22‡C.
3. Results
3.1. Functional promoter analysis
The activity of the di¡erent XOR promoter luciferase con-
structs was studied in transient transfection assays in 293T
and NIH-3T3 cells. XOR5 corresponding to the promoter
region from 3142 to +42, relative to the translational initia-
tion site, showed the highest promoter activity in 293T cells,
the activity being V10-fold higher than that of the promoter-
less pGL3-basic, whereas XOR6 (from 392 to +42) was less
active (Fig. 1A). Interestingly, the promoter activities of the
longer constructs, XOR1, XOR2, and XOR3, were approxi-
mately one third of the activity of XOR5 (Fig. 1A), suggesting
a repressor binding to the promoter. XOR1 gave the highest
activity in NIH-3T3 cells (Fig. 1B).
3.2. DNA^protein interactions of the proximal XOR promoter
A sequence analysis of the promoter region from 3142 to
392, which is included in XOR5 but not in XOR6, revealed
two inverted CCAAT motifs (Fig. 1C). EMSAs were per-
formed using nuclear extracts from 293T and NIH-3T3 cells
and labelled XOR5E and oligo1 as probes. Both nuclear ex-
tracts yielded a strong retarded band of the same size with
XOR5E, which was competed by a 100-fold molar excess of
unlabelled XOR5E (Fig. 2A). When a double-stranded oligo-
nucleotide oligo1, corresponding to the nucleotides from
3135 to 3107 of the XOR promoter and encompassing one
of the putative CCAAT motifs, was used in EMSAs, two
(293T cells) or one (NIH-3T3 cells) speci¢c DNA^protein
Fig. 2. Characterization of the XOR promoter region interacting with nuclear proteins. A: Nuclear proteins (10 Wg) extracted from 293T or
NIH-3T3 cells were incubated with 32P-labelled XOR5E, corresponding to region 3142 to +42 of the human XOR promoter. The major specif-
ic protein^DNA complex formed is indicated with an arrow. Unlabelled XOR5E was used in competition experiments in 100-fold molar excess.
B: 32P-labelled oligo1 corresponding to the promoter region 3135 to 3107 was incubated with nuclear proteins as above. The strong retarded
band (indicated with an arrow) formed by both nuclear extracts was e⁄ciently competed with 100-fold molar excess of unlabelled oligo1.
C: The binding of proteins to 32P-labelled XOR5E (corresponding to region 3142 to +42 of the XOR promoter) was competed with 70-fold
molar excess of oligo1. The arrow indicates the band formed by both, 293T and NIH-3T3, nuclear extracts. D: The binding of nuclear proteins
extracted from 293T cells to 32P-labelled oligo1 was competed with 10-, 50- or 100-fold molar excess of unlabelled consensus C/EBP oligomer
or 10-, 50- or 100-fold molar excess of unlabelled oligo1 as depicted.
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complexes were formed (Fig. 2B,D). In the presence of unla-
belled oligo1 in molar excess, the major complex formed by
protein binding to XOR5E was markedly attenuated (Fig.
2C), demonstrating that the region 3135 to 3107 is important
for the protein binding.
The transcription factors NF-Y, C/EBP, nuclear factor 1
(NF1), and CCAAT displacement protein (CDP) can all po-
tentially bind to the CCAAT motif [26]. In order to identify
the protein speci¢cally binding to the promoter region 3135
to 3107, competitive binding reactions were performed. Nei-
ther the consensus (Fig. 2D) nor the mutated (data not
shown) C/EBP oligonucleotides competed out the binding to
oligo1 even in 100-fold molar excess. The oligo1^protein com-
plex was not in£uenced by C/EBP-L antibody (data not
shown). Neither did C/EBP oligonucleotide or C/EBP-L anti-
body change the protein binding pattern to XOR5E (data not
shown), indicating that C/EBP is not capable of binding to
this region of the proximal XOR promoter in vitro. NF-Y
consensus oligonucleotide, on the other hand, competed out
the protein binding to oligo1 and XOR5E, and CBF-A/NF-Y-
B antibody recognized the bound protein in supershift experi-
ments (Fig. 3A,B). Together these results indicate that the
protein interacting with the XOR promoter DNA is indeed
NF-Y.
3.3. Functional analysis of the XOR promoter CCAAT motif
We mutated the putative NF-Y binding site to evaluate its
functional role in human XOR gene transcriptional regula-
tion. In EMSA, XOR5Emut with the mutated CCAAT motif
did not compete with the binding of the protein recognized by
NF-Y antibody on XOR5E (data not shown). Neither did
XOR5Emut compete with the protein binding to oligo1,
whereas XOR5E did (Fig. 3C), demonstrating the importance
of the intact CCAAT motif in the binding of the transcription
factor NF-Y. In transiently transfected 293T cells, the activity
of the promoter construct with the mutated CCAAT site
(XOR5mut) was reduced by 45% compared to the intact
XOR5 (Fig. 1A), indicating that the motif is indeed mediating
transcriptional activation of XOR gene promoter in intact
cells.
4. Discussion
We have characterized the transcriptional regulation of the
human XOR gene by studying the promoter activity in tran-
sient transfections with a 5P deletion series. A fragment cor-
responding to the human XOR promoter from 3142 to +42
(XOR5) yielded the highest promoter activity of the series in
human 293T cells. Comparison of the activities provided by
both shorter and longer fragments suggests the presence of
positive regulatory elements between 392 and 3142, and neg-
ative regulatory elements in the region upstream of 3224. Xu
et al. recently reported that the region from 3258 to 3228,
harboring an E-box, represses basal promoter activity in
HepG2 cells and in HUVECs [22], which is in accordance
with our ¢ndings. In contrast with the report by Xu et al.
[22], we did not detect an increase in the promoter activity
by extending the 5P-end of the promoter fragment from 3142
to 3224. Di¡erent cell lines used for transfection experiments
could account for the di¡erences in promoter activity. Also
the fact that our promoter constructs included the translated
nucleotides of the ¢rst exon (up to +42) may have contributed
to the di¡erences. Interestingly, the coding region of the ¢rst
exon of the rat XOR gene harbors transcription factor bind-
Fig. 3. Identi¢cation of NF-Y as the nuclear protein binding to the XOR promoter CCAAT motif. A: 32P-labelled oligo1 (3135 to 3107) was
incubated with nuclear proteins (10 Wg) extracted from 293T or 3T3 cells. Unlabelled NF-Y consensus oligomer was used in 10- (NF-Y U10)
or 100-fold (NF-Y U100) molar excess in competition experiments. Antibodies against NF-Y (NF-Y ab) or GATA-6 (GATA-6 ab, used as a
control) were used in supershift experiments. Arrows indicate supershifted complexes seen with NF-Y antibody. B: Nuclear proteins from
NIH-3T3 cells were incubated with 32P-labelled XOR5E (3142 to +42). NF-Y or GATA-6 antibodies were used in supershift experiments.
Supershift seen on lane 2 is indicated with arrow. Unlabelled NF-Y oligomer was used in 10- or 100-fold molar excess in competition experi-
ments. C: 32P-labelled oligo1 was incubated with nuclear proteins (10 Wg) extracted from 293T cells. The binding of proteins was competed
with 100-fold molar excess of unlabelled XOR5E (3142 to +42) or XOR5Emut containing a mutated CCAAT motif.
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ing sites that have a functional role in promoter regulation
[27].
The region of the human XOR promoter that was crucial
for maximal activity contains two putative CCAAT motifs.
The transcription factors NF-Y, NF1, C/EBP, and CDP can
all potentially bind to the consensus CCAAT motif [26],
which is one of the most common elements in the proximal
promoter of many mammalian genes transcribed by RNA
polymerase II [28]. C/EBP regulates many liver-speci¢c genes
and is involved in in£ammatory responses [29]. C/EBP-L and
C/EBP-K were shown to bind to the proximal promoter of the
TATA-less rat XOR promoter [30], whereas enhancer binding
factor I, closely resembling NF-Y did not bind to this pro-
moter [31]. C/EBP also regulated the basal transcription of the
rat gene together with downstream elements located in the
coding region [27]. However, the rat C/EBP binding site is
not conserved in the human promoter (Fig. 1C), which is in
line with our ¢nding that C/EBP does not bind to human
XOR promoter.
Our data indicate that NF-Y binds to the CCAAT motif,
located between nucleotides 3119 and00000 3123 from the
translational start site of the proximal human XOR gene pro-
moter. The CCAAT motif is conserved in rat and man and
partly overlaps the reported rat C/EBP binding site. In the
human XOR promoter, two putative transcription start sites
located 59 and 81 nucleotides upstream of the start codon
have been identi¢ed [19]. Our ¢nding that NF-Y binds to a
CCAAT motif located at 360 from the ¢rst transcriptional
initiation site is in accordance with the typical location of the
CCAAT motif [28]. Furthermore, mutation of the NF-Y site
severely compromised the promoter activity, indicating that
the site is functional in intact cells, thus suggesting an impor-
tant functional role for NF-Y in the transcriptional regulation
of the human XOR gene.
The reason for the di¡erences in the tissue expression of
XOR between man and rodents is unclear. Xu et al. reported
a considerably lower transcriptional activity of the human
gene compared to that of the mouse gene [22]. The proximal
rat and mouse promoters are very similar [32,33], whereas the
promoters of the human and rat genes show only limited se-
quence similarities in (Fig. 1C). Taken together, this suggests
that transcriptional regulation may account for the species
speci¢c expression of the XOR gene.
NF-Y is a ubiquitous transcription factor that binds to
DNA as a heterotrimer. It has been shown to interact with
the TATA-binding protein [34], with di¡erent coactivators,
such as p300 [35], and to promote the binding of other tran-
scription factors to nearby sequences [28]. For instance, in the
promoter of the liver speci¢c albumin gene, the precise posi-
tioning of C/EBP next to NF-Y is required for optimal acti-
vation [36]. However, the trans-acting factor or factors coop-
erating with NF-Y in the human XOR gene regulation are not
known. Identifying these factors will be crucial in order to
understand the regulation of the human XOR gene in re-
sponse to various extracellular signals.
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